HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nonprofit Pharmaceutical Companies

419.757

-17.440-3.99%

Number of Gainers:5

Number of Losers:27

Number of Flat:2

PE:- -

High:441.043

Open:436.588

Low:416.263

Close:437.197

Loading ...

CARsgen Therapeutics - Introduction of Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China

THOMSON REUTERS

CARsgen Therapeutics - Investment Fund to Subscribe for Additional Registered Capital of Ucarsgen Biotech for RMB80 Mln

THOMSON REUTERS

InnoCare Pharma Anti-MS Drug Selected for Phase 3 Studies Following Efficacy, Safety Results

MT Newswires Live

Basecare Medical Unit to Collaborate with Rhea Labs on AI-Powered IVF Clinics

MT Newswires Live

HBM Joint Venture Strikes Licensing Deal to Advance Novel CRH Therapies

MT Newswires Live

BRIEF-Suzhou Basecare Medical Corp Enters Into Strategic Cooperation Agreement

Suzhou Basecare Medical Corp - Agreement to Establish Model Artificial Intelligence-Powered in Vitro Fertilization (IVF) Clinics

THOMSON REUTERS

Suzhou Basecare Medical Corp - Entering Into Strategic Cooperation Agreement With Rhea Labs Pte. Ltd

THOMSON REUTERS

CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China

THOMSON REUTERS

Genor Biopharma - Co and Target Are in Course of Preparing New Listing Application

THOMSON REUTERS

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination With Pfizer's Adcs

THOMSON REUTERS

Summit Therapeutics, Pfizer to Study Ivonescimab/ADC Combos

CanSino Biologics Gets Clinical Trial Appproval from NMPA for Influenzae Type B Vaccine

MT Newswires Live

BRIEF-CanSino Biologics Says DTcP-Hib-MCV4 Combined Vaccine Obtains Clinical Trial Approval By NMPA China

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/BK1574/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":419.75656,"timestamp":1741594084391,"preClose":437.19687,"halted":0,"volume":125062844,"delay":0,"changeRate":-0.039891,"change":-17.440308,"pbRate":3.43319,"amount":2228559126,"amplitude":0.056681,"prevYearClose":331.1933,"fiveDayClose":410.09,"twentyDayClose":340.813,"turnoverRate":0.004845,"marketCap":234571806688,"floatMarketCap":221135631584,"peRate":-17.305245},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":441.04327,"amplitude":0.056681,"preClose":437.19687,"low":416.2626,"pbRate":"3.43319","latestPrice":419.75656,"volume":125062844,"delay":0,"open":436.5877,"prevYearClose":331.1933,"prevWeekClose":437.197,"prevMonthClose":411.011,"prevQuarterClose":331.193,"fiveDayClose":410.09,"twentyDayClose":340.813,"sixtyDayClose":341.701,"secType":"PLATE","market":"HK","turnoverRate":0.004845,"peRate":-17.305245,"marketCap":234571806688,"floatMarketCap":221135631584,"timestamp":1741594084391,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":5,"down":27,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:16,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514885860","title":"CARsgen Therapeutics - Introduction of Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China","url":"https://stock-news.laohu8.com/highlight/detail?id=2514885860","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514885860?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:50","pubTimestamp":1740577818,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PH1JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02171","BK1574","BK1585","BK1587"],"gpt_icon":0},{"id":"2514858139","title":"CARsgen Therapeutics -  Investment Fund to Subscribe for Additional Registered Capital of Ucarsgen Biotech for RMB80 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514858139","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514858139?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:50","pubTimestamp":1740577818,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PH1JN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1585","BK1587","02171","BK1574"],"gpt_icon":0},{"id":"2514837691","title":"InnoCare Pharma Anti-MS Drug Selected for Phase 3 Studies Following Efficacy, Safety Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514837691","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514837691?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:06","pubTimestamp":1740575217,"startTime":"0","endTime":"0","summary":"InnoCare Pharma  said the 80 mg once daily dose of its BTK inhibitor, Orelabrutinib, for the treatment of relapsing-remitting multiple sclerosis, was selected for phase 3 progressive multiple sclerosis studies following a demonstration of efficacy and safety profile.The company's phase 2 results were released at the 10th annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum. These results will be presented as the on-site poster at the forum on Thursday, a Wednesday bourse filing said.Orelabrutinib is a selective brain-penetrant BTK inhibitor that inhibits B cell, microglia, and macrophage activation in the central nervous system along with inhibiting macrophage activation.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4534","LU0320765646.SGD","LU2357305700.SGD","LU1720051108.HKD","BK4581","688428","LU2111349929.HKD","BK4504","LU0795875086.SGD","LU0795875169.SGD","LU2089284900.SGD","LU0158827781.USD","LU1732799900.SGD","BK0239","LU1668664300.SGD","IE00BKVL7J92.USD","LU2133065610.SGD","LU1074936037.SGD","LU0912757837.SGD","09969","LU0314104364.USD","LU1720051017.SGD","LU0971096721.USD","BK1161","BK4516","LU2089283258.USD","LU0098860793.USD","BK4588","LU2028103732.USD","LU0106261372.USD","IE00BZ1G4Q59.USD","BK4127","LU0267386448.USD","LU1363072403.SGD","LU2271345857.HKD","LU2347655156.SGD","LU0225283273.USD","LU1162221912.USD","LU0106831901.USD","LU1989772923.USD","LU2023251221.USD","LU0006306889.USD","LU1989772840.SGD","LU1732800096.USD","LU1548497426.USD","LU0158827948.USD","BK4585","BK1574"],"gpt_icon":0},{"id":"2514594838","title":"Basecare Medical Unit to Collaborate with Rhea Labs on AI-Powered IVF Clinics","url":"https://stock-news.laohu8.com/highlight/detail?id=2514594838","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514594838?lang=en_us&edition=fundamental","pubTime":"2025-02-26 18:53","pubTimestamp":1740567199,"startTime":"0","endTime":"0","summary":"Suzhou Basecare Medical's  subsidiary Genea Biomedx agreed to cooperate with Rhea Labs to establish model artificial intelligence-powered in vitro fertilization clinics.The five-year strategic cooperation will see the parties jointly expand the assisted reproductive industry markets across the US, Europe, South America, and Southeast Asia, a Tuesday bourse filing said.Under the tie-up, Genea Biomedx will provide medical products and comprehensive solutions to support the development of Rhea Labs' reproductive institutions and jointly collaborate to develop AI-powered new products.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02170","NPL.SI","BK1574","BK6100","BK1597","BK1222"],"gpt_icon":0},{"id":"2514005902","title":"HBM Joint Venture Strikes Licensing Deal to Advance Novel CRH Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2514005902","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514005902?lang=en_us&edition=fundamental","pubTime":"2025-02-26 14:39","pubTimestamp":1740551973,"startTime":"0","endTime":"0","summary":"HBM Holdings'  joint venture with Boston Children's Hospital, HBM Alpha Therapeutics, agreed to collaborate with an unnamed business partner to advance novel therapies targeting corticotropin-releasing hormone or CRH for multiple disorders.Under the tie-up, the partner gets exclusive global rights to develop and commercialize HBM9013, an anti-CRH-neutralizing antibody. The license excludes China, Hong Kong, Taiwan and Macau.In return, HBM Alpha will receive up to $395 million, including upfront, development, regulatory, and commercial milestone payments, as well as tiered royalties on future net product sales.Additionally, HBM Alpha is entitled to a minority interest in the business partner, according to a Wednesday bourse filing.HBM9013 is an antibody program developed by the group for CRH-related disorders, including congenital adrenal hyperplasia, a group of diseases caused by gene mutations.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","LU1035777561.USD","LU0314106906.USD","LU2463526074.USD","LU1093756325.SGD","BK4185","GB00BDT5M118.USD","BK4011","LU0128525929.USD","BK1574","JYNT","LU1863844665.USD","LU1291149836.SGD","LU0942090050.USD","LU1019632923.USD","LU1019634622.SGD","LU2298321311.HKD","BK1583","LU0310800379.SGD","LU2041044095.USD","LU0238689110.USD","LU0868494617.USD","02142","LU1093756168.USD","LU2360108059.USD","LU1506573853.SGD","LU0708994859.HKD","CRH","LU1039938227.USD","LU1863844749.USD","LU2092937221.SGD","LU1267930573.SGD","LU1880398554.USD","LU1880398471.USD","LU0868494708.USD","LU0029864427.USD"],"gpt_icon":0},{"id":"2514011981","title":"BRIEF-Suzhou Basecare Medical Corp Enters Into Strategic Cooperation Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2514011981","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514011981?lang=en_us&edition=fundamental","pubTime":"2025-02-26 00:34","pubTimestamp":1740501273,"startTime":"0","endTime":"0","summary":"BRIEF-Suzhou Basecare Medical Corp Enters Into Strategic Cooperation AgreementFeb 25  - Suzhou Basecare Medical 2170.HK:ENTERING INTO STRATEGIC COOPERATION AGREEMENT WITH RHEA LABS PTE. LTDAGREEMENT TO ESTABLISH MODEL ARTIFICIAL INTELLIGENCE-POWERED IN VITRO FERTILIZATION  CLINICSFurther company coverage: 2170.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG0D9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02170","BK1574","BK1222","BK1597"],"gpt_icon":0},{"id":"2514509407","title":"Suzhou Basecare Medical Corp - Agreement to Establish Model Artificial Intelligence-Powered in Vitro Fertilization (IVF) Clinics","url":"https://stock-news.laohu8.com/highlight/detail?id=2514509407","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514509407?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:57","pubTimestamp":1740491878,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG0D9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02170","BK1222","BK1574","BK1597"],"gpt_icon":0},{"id":"2514209421","title":"Suzhou Basecare Medical Corp - Entering Into Strategic Cooperation Agreement With Rhea Labs Pte. Ltd","url":"https://stock-news.laohu8.com/highlight/detail?id=2514209421","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514209421?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:57","pubTimestamp":1740491878,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG0D9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02170","BK1597","BK1222","BK1574"],"gpt_icon":0},{"id":"2514609671","title":"CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China","url":"https://stock-news.laohu8.com/highlight/detail?id=2514609671","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514609671?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:01","pubTimestamp":1740488473,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG0KF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1161","BK1585","02171","BK1574"],"gpt_icon":0},{"id":"2514706637","title":"Genor Biopharma - Co and Target Are in Course of Preparing New Listing Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2514706637","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514706637?lang=en_us&edition=fundamental","pubTime":"2025-02-25 17:54","pubTimestamp":1740477271,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PF25N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","06998","BK1161","BK1583"],"gpt_icon":0},{"id":"2514086204","title":"Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination With Pfizer's Adcs","url":"https://stock-news.laohu8.com/highlight/detail?id=2514086204","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514086204?lang=en_us&edition=fundamental","pubTime":"2025-02-25 09:14","pubTimestamp":1740446043,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nTUA8P9HQD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1794554557.SGD","BK1161","IE00B543WZ88.USD","LU0348783233.USD","IE00BPRC5H50.USD","LU1720050803.USD","09926","IE00B5MMRT66.SGD","LU2488822045.USD","LU0348784397.USD","LU0417516571.SGD","BK1574"],"gpt_icon":0},{"id":"2513408847","title":"Summit Therapeutics, Pfizer to Study Ivonescimab/ADC Combos","url":"https://stock-news.laohu8.com/highlight/detail?id=2513408847","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513408847?lang=en_us&edition=fundamental","pubTime":"2025-02-24 19:44","pubTimestamp":1740397440,"startTime":"0","endTime":"0","summary":"Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.Summit on Monday said the companies plan to evaluate ivonescimab in combination with several Pfizer ADCs across multiple solid tumor settings to determine the safety profile and potential anti-tumor activity of the combinations.Miami biopharmaceutical company Summit said it will provide ivonescimab for use in the proposed studies, slated to begin in the middle of the year, with New York drugmaker Pfizer being responsible for conducting the studies.Summit has licensed the rights to ivonescimab in North and South America, Europe, the Middle East, Africa and Japan from Chinese biotech Akeso, which engineered the drug.Summit last year reported data from a late-stage study that showed ivonescimab beat Merck's blockbuster cancer drug Keytruda in patients with a form of lung cancer.Pfizer is developing several ADCs, whi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051225.USD","LU0321505868.SGD","LU0320765489.SGD","LU1035773651.USD","LU1989772840.SGD","LU1989772923.USD","SG9999001176.USD","LU0348784397.USD","LU0265550359.USD","LU0234572021.USD","MRK","LU2461242641.AUD","LU1023059063.AUD","BK4568","LENZ","LU0203347892.USD","SG9999014542.SGD","IE0002270589.USD","LU1571399168.USD","LU2468319806.SGD","09926","LU1974910355.USD","LU2324357040.USD","IE00B2B36J28.USD","BK1574","IE00BFTCPJ56.SGD","LU1794554557.SGD","LU1941712264.USD","SG9999013999.USD","BK4559","LU0965508806.USD","LU0965509283.SGD","LU0985481810.HKD","BK1161","SG9999015358.SGD","LU1069347547.HKD","BK4592","LU0306807586.USD","LU0965509101.SGD","SG9999002224.SGD","SMMT","ADC","BK4516","SMMF","BK4007","BK4581","IE00BN8TJ469.HKD","PFE","LU1066051811.HKD","BK4533"],"gpt_icon":0},{"id":"2513749028","title":"CanSino Biologics Gets Clinical Trial Appproval from NMPA for Influenzae Type B Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2513749028","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513749028?lang=en_us&edition=fundamental","pubTime":"2025-02-24 19:00","pubTimestamp":1740394825,"startTime":"0","endTime":"0","summary":"CanSino Biologics  said it obtained clinical trial approval granted by China's National Medical Products Administration to initiate a clinical trial for the Company's Influenzae Type B, according to a Monday filing with the Hong Kong bourse.The DTcP-Hib-MCV4 Combined Vaccine contains components for diphtheria, tetanus, and acellular pertussis , Haemophilus Influenzae Type b , and Group ACYW135 meningococcal  protection.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1191","BK0239","BK1515","06185","688185","BK1574"],"gpt_icon":0},{"id":"2513823746","title":"BRIEF-CanSino Biologics Says DTcP-Hib-MCV4 Combined Vaccine Obtains Clinical Trial Approval By NMPA China","url":"https://stock-news.laohu8.com/highlight/detail?id=2513823746","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513823746?lang=en_us&edition=fundamental","pubTime":"2025-02-24 18:20","pubTimestamp":1740392406,"startTime":"0","endTime":"0","summary":"BRIEF-CanSino Biologics Says DTcP-Hib-MCV4 Combined Vaccine Obtains Clinical Trial Approval By NMPA ChinaFeb 24  - CanSino Biologics Inc 688185.SS:DTCP-HIB-MCV4 COMBINED VACCINE OBTAINS CLINICAL TRIAL APPROVAL BY NMPA CHINAFurther company coverage: 688185.SS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PF10W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1515","BK1161","BK0239","BK1574","06185","688185"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":4,"totalSize":62}]}}